To demonstrate the functions and features of CDI-CASP, we conducted the search of synthesis routes of S-Zanubrutinib, a molecule for the treatment of lymphoma; commercial name Brukinsa. A synthesis route filed in a recent patent was chosen as the benchmark route, as shown in Fig. . This synthesis route consists of 12-steps (three parallel steps from two feedstocks) and involves many hazardous molecules.